about
Current and emerging azole antifungal agentsCrystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infectionsEffects of an acidic beverage (Coca-Cola) on absorption of ketoconazoleApplication of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysisA randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patientsIn-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleriIn vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogensPhytochemical Composition, Antifungal and Antioxidant Activity of Duguetia furfuracea A. St.-HillEvidence for digenic inheritance in some cases of Antley-Bixler syndrome?Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in JapanCerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): a taxonomic update and review of the literature.Fluconazole therapy in Candida albicans spondylodiscitis.Passive immunity against human pathogens using bovine antibodies.Treatment of histoplasmosis with MK-991 (L-743,872)Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicansMetabolism-based drug interactions involving oral azole antifungals in humans.Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.The new oral antifungal agents for onychomycosis of the toenails.Prenatal exposure to antifungal medication may change anogenital distance in male offspring: a preliminary studyClinical and laboratory update on blastomycosis.Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitisEfficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrInteraction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750Interactions between triazoles and amphotericin B against Cryptococcus neoformans.New investigational antifungal agents for treating invasive fungal infections.Endemic mycosis complicating human immunodeficiency virus infection.Fluconazole dose recommendation in urinary tract infection.Intravenous itraconazole.Fluconazole in transplant recipients: options and limitations.Fungal infections in older adults.Genitourinary fungal infections: a therapeutic conundrum.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infectionManagement of histoplasmosis.Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.Antifungal drug resistance.Epidemiology, pathology and treatment of cutaneous leishmaniasis in taif region of saudi arabiaAddition of caspofungin to fluconazole does not improve outcome in murine candidiasis.Use of amphotericin B with azole antifungal drugs: what are we doing?
P2860
Q24550733-2A9C151F-55CD-4A44-9C16-AF9F59662C48Q24648110-BEB995AD-7A37-48D8-9839-BD05F68079ECQ24676913-71C8BF2F-1B58-41FE-8DC8-6B546E1BD445Q27681973-1BBAF60F-5853-4409-AE67-B72AC48A2B1BQ28067438-FA362EEA-19CB-4588-9EA9-9C2D18BAA3B9Q28189320-8596ABF1-BFCE-4BC3-8503-D3F972361284Q28304841-CB85DA1C-1D11-413D-A482-57BE8443E799Q28343832-35B56D44-6204-494D-BBB1-7238C0D88605Q28834586-FD986F1F-81BE-4F35-A759-E211E0AC5F29Q30443021-60A62CEB-C3FF-4A38-B8D4-45BE92F9CA09Q30577215-01ED5326-A8F8-4780-BF01-025D4F91F4E8Q33514740-B6C401E2-4313-411F-A683-3F64D90AE66CQ33538418-5CC912F8-2BAB-4C05-9914-9A51EF715942Q33640433-96AE16A9-0600-4557-A90E-366E21BAE15AQ33690643-2285B97C-95F5-48B3-8B02-B3927F883778Q33695613-71DAEE8D-C676-4256-BAFF-01D4216AEFBAQ33719828-76FC8843-C444-492A-BD08-2E331450218FQ33721804-CE5FFBB9-8F40-4E03-A492-089084273E54Q33775734-46D1BC7F-3B53-422E-85CB-5034FA3FB679Q33823713-F11ED3F0-0D56-4A76-BE3B-BCBF6554A6FCQ33825592-48BEAF1B-BD48-41D4-A5E5-AB106A29DA39Q33936017-8CBC305D-CCEF-4EE3-B1F5-5AFA3EECF928Q33978188-D1CE13D3-930C-4A78-B187-91ABC7D220E0Q33978197-296619AB-26FB-4461-896A-494539DA1976Q33979724-FD3CDDE6-FACE-4E87-8D1B-4C80BE7BD9C3Q33980497-E5667E8B-EC8A-4971-B4F3-F8E1FC9D46C1Q34075014-CC177285-6C8D-4678-83C2-C5833610D9D4Q34183291-8B987A3E-FC6A-435B-A1CE-68DAFCA3C6D8Q34191338-86D70E30-39E4-4337-910C-2D5327601A78Q34284268-B340F0D5-2CE2-4019-A530-2A43EAD892ECQ34294909-035670F2-F54C-4669-93B6-ECE643E95608Q34312894-A16CCAFC-D35C-40AF-8BA3-D6F5B95028E4Q34390174-28E0A9AE-EF6A-4048-9909-B0C7683AF106Q34633796-07E9F311-B1B9-4AEF-90E7-505769C60384Q34768480-49376A28-5896-4C27-A79A-2CDA3152217EQ34998102-1482A64C-F617-4F28-BCE9-111598E70063Q35040008-31863344-4B9D-49BC-B87A-F3DF70189AD2Q35047334-5C8F7BFE-0709-4238-B876-8011F14E6E39Q35102603-7AED87E3-5826-46BE-836C-8078151EF969Q35117932-EB910DF8-0F50-4634-A57B-7D3EC52EDFAD
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Oral azole drugs as systemic antifungal therapy.
@en
type
label
Oral azole drugs as systemic antifungal therapy.
@en
prefLabel
Oral azole drugs as systemic antifungal therapy.
@en
P1476
Oral azole drugs as systemic antifungal therapy.
@en
P2093
P304
P356
10.1056/NEJM199401273300407
P407
P577
1994-01-01T00:00:00Z